Abstract
Neratinib was recently approved by the FDA for extended adjuvant treatment of HER2+ breast cancer. The ExteNET trial showed improvement in invasive disease-free survival (iDFS) in the neratinib armcompared with placebo. The benefit was more pronounced in patients with estrogen receptor-positive (ER+)/ HER2+ tumors, suggesting bidirectional cross-talk between the ER and HER pathways.
Original language | English (US) |
---|---|
Pages (from-to) | 3483-3485 |
Number of pages | 3 |
Journal | Clinical Cancer Research |
Volume | 24 |
Issue number | 15 |
DOIs | |
State | Published - Aug 1 2018 |
ASJC Scopus subject areas
- Oncology
- Cancer Research